News Sentiment

AKTS sentiment intelligence

Aktis Oncology, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 24.89 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-10.7% over one week, +3.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend inactive 3.3% over four weeks
Fair value 19.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 47
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 10
Stock Titan 9
Moomoo 3
Investing.com Nigeria 3
GlobeNewswire 3
Bitget 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 15
Analyst action 5
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Simply Wall Street Direct company coverage

Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?

Aktis Oncology (AKTS) stock has recently fallen by 16.3%, but current valuations still lean towards expensive rather than undervalued, passing only 2 of 6 valuation tests. The company's P/B ratio of 2.6x is in line with the biotech industry average, suggesting it's roughly fairly

Tone
Negative 38/100
Event
Market update
Published
24 Jul 2026 04:40
Source
Simply Wall Street
Moomoo Direct company coverage

Aktis Oncology Inc : Leerink Partners Assumes

This article states that Leerink Partners has initiated coverage on Aktis Oncology Inc. The content is very brief, serving primarily as an announcement of this new analyst coverage.

Tone
Neutral 50/100
Event
Analyst action
Published
22 Jul 2026 16:11
Source
Moomoo
Investing.com Nigeria Direct company coverage

Form 4 Aktis Oncology Inc For: 21 July By Investing.com

The article reports that Aktis Oncology Inc. filed a Form 4 for July 21. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. This filing indicates transactions in

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 01:41
Source
Investing.com Nigeria
Investing.com Direct company coverage

Aktis Oncology director Ken Herrmann sells $119,274 in stock

Aktis Oncology director Ken Herrmann sold 4,856 shares of common stock for $119,274 on July 20, 2026, after exercising fully vested stock options. This sale follows a period of strong stock performance for Aktis, which has seen its shares rise nearly 10% in the past six months. S

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 01:41
Source
Investing.com
Bitget Direct company coverage

Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78

Aktis Oncology director Ken Herrmann sold 4,856 common shares on July 20, 2026, at $24.56 per share, totaling $119,256.78. He had acquired these shares previously through option exercises at much lower prices. Following these transactions, his direct common stock holding fell to

Tone
Negative 31/100
Event
Market update
Published
22 Jul 2026 00:41
Source
Bitget
Stock Titan Direct company coverage

Aktis Oncology (AKTS) director sells 4,856 shares after exercising options

Aktis Oncology director Ken Herrmann exercised options for 4,856 shares at various strike prices and subsequently sold all those shares for approximately $119,000 gross proceeds. The transactions, which involved both execution of options and sale of common stock, were completed o

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 03:41
Source
Stock Titan
Stock Titan Direct company coverage

Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise

Ken Herrmann, a director at Aktis Oncology, Inc. (AKTS), executed a same-day option exercise and sale. He exercised 3,065 stock options at $0.08 per share and immediately sold these 3,065 shares at a weighted average price of $25.2067. After the transaction, Herrmann retains 3,50

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 21:11
Source
Stock Titan
TradingView Direct company coverage

AKTS Options Chain — NASDAQ:AKTS

This page provides an options chain for Aktis Oncology, Inc. (AKTS) on the Nasdaq Stock Market. It allows users to monitor live pricing, Greeks, implied volatility, and other key metrics for available call and put options contracts. The platform emphasizes evaluating market movem

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 12:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS

This article provides "Enterprise value to revenue forward" data for Aktis Oncology, Inc. (NASDAQ: AKTS) on TradingView. The content indicates a period, a value, and change percentages, noting that the data was "Made by humans."

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 03:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Aktis Oncology, Inc. – NASDAQ:AKTS

The article focuses on the enterprise value to EBIT forward ratio for Aktis Oncology, Inc. (NASDAQ: AKTS). It appears to be a financial data page from TradingView, providing an overview of a specific financial metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 17:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com

This article from Investing.com reports on a Form 144 filing for Aktis Oncology, specifically for July 17. The content provided is minimal, essentially just stating the filing and date without furnishing any details about the filing itself. The majority of the page consists of we

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 02:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[144] Aktis Oncology, Inc. SEC Filing

This article reports on an SEC Form 144 filing by Aktis Oncology, Inc. (AKTS) detailing a proposed sale of securities. The filing indicates a stock option exercise by an individual, with 3065 shares of common stock valued at $77,258.54 to be sold through Morgan Stanley Smith Barn

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 21:10
Source
Stock Titan
TradingView Direct company coverage

AKTS Options Volatility — NASDAQ:AKTS

This article provides an overview of Aktis Oncology, Inc. (AKTS) options volatility on TradingView. It highlights implied volatility curves and at-the-money (ATM) implied volatility across different expirations, offering tools for traders to assess market expectations and identif

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 20:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Aktis Oncology, Inc. – NASDAQ:AKTS

This page from TradingView provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically focusing on its forward price-to-sales ratio. It lists the company's financial data, news, and community sentiment within the platform's interface. The article itself d

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 14:10
Source
TradingView
GuruFocus Direct company coverage

New Options Listings Include Aktis Oncology Inc (AKTS)

Aktis Oncology Inc (AKTS) has been added to new options listings, reflecting a growing interest in diverse investment opportunities in the biotechnology sector. Despite this, AKTS has a low GF Score™ of 9/100 and a high price-to-sales ratio, indicating significant future growth e

Tone
Negative 40/100
Event
Market update
Published
15 Jul 2026 13:15
Source
GuruFocus
Moomoo Direct company coverage

J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33

J.P. Morgan has reiterated its Buy rating on Aktis Oncology (AKTS.US), indicating continued confidence in the company's prospects. The firm also raised its target price for Aktis Oncology shares to $33, suggesting an increased positive outlook on the stock's future performance. T

Tone
Positive 71/100
Event
Analyst action
Published
15 Jul 2026 02:10
Source
Moomoo
GuruFocus Direct company coverage

AKTS Maintained by JP Morgan -- Price Target Raised to $33.00

JP Morgan has maintained an Overweight rating on Aktis Oncology (AKTS), increasing its price target from $30.00 to $33.00. This reflects growing confidence in the company's targeted radiopharmaceuticals, despite a low GF Score™ of 9/100, which indicates potential financial and gr

Tone
Positive 67/100
Event
Analyst action
Published
14 Jul 2026 15:11
Source
GuruFocus
TradingView Direct company coverage

Price to book forward of Aktis Oncology, Inc. – NASDAQ:AKTS

This article provides key financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically its "Price to book forward" value. It indicates that the market was closed and no trades were made at the time of publication, with data provided by ICE Data Services and FactSet

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 00:12
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Aktis Oncology, Inc. – NASDAQ:AKTS

This article provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically its "Price to earnings forward" metric. The content points to data sourced from ICE Data Services and FactSet, and indicates the market for AKTS shares was closed with no trades at t

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 21:41
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Aktis Oncology Inc For: 10 July By Investing.com

This article from Investing.com announces a Form 4 filing for Aktis Oncology Inc. for July 10. It is a brief report providing information on insider transactions for the company (AKTS).

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:40
Source
Investing.com Nigeria
Investing.com Canada Direct company coverage

Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com

Aktis Oncology's Chief Operating Officer, Ron-Bigger Shulamit, sold approximately $1.39 million worth of company shares on July 8, 2026. The transaction involved exercising stock options and then immediately selling the acquired 50,000 shares, which had a vesting schedule startin

Tone
Negative 35/100
Event
Market update
Published
10 Jul 2026 10:22
Source
Investing.com Canada